학술논문
Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS
Document Type
Abstract
Author
Source
In Blood 15 November 2022 140 Supplement 1:7699-7700
Subject
Language
ISSN
0006-4971